CA2730531A1 - Medical use of the radical scavenger and antioxidant alpha-1-microglobulin - Google Patents

Medical use of the radical scavenger and antioxidant alpha-1-microglobulin Download PDF

Info

Publication number
CA2730531A1
CA2730531A1 CA2730531A CA2730531A CA2730531A1 CA 2730531 A1 CA2730531 A1 CA 2730531A1 CA 2730531 A CA2730531 A CA 2730531A CA 2730531 A CA2730531 A CA 2730531A CA 2730531 A1 CA2730531 A1 CA 2730531A1
Authority
CA
Canada
Prior art keywords
microglobulin
alpha
cells
heme
haemoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2730531A
Other languages
English (en)
French (fr)
Inventor
Martin Lennarth Olsson
Stefan Hansson
Bo Akerstroem
Magnus Olsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
A1M Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma AB filed Critical A1M Pharma AB
Publication of CA2730531A1 publication Critical patent/CA2730531A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
CA2730531A 2008-07-18 2009-07-17 Medical use of the radical scavenger and antioxidant alpha-1-microglobulin Abandoned CA2730531A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US13533808P 2008-07-18 2008-07-18
US61/135,338 2008-07-18
DKPA200801024 2008-07-18
DKPA200801024 2008-07-18
US18938108P 2008-08-18 2008-08-18
DKPA200801116 2008-08-18
US61/189,381 2008-08-18
DKPA200801116 2008-08-18
US19750608P 2008-10-27 2008-10-27
DKPA200801478 2008-10-27
US61/197,506 2008-10-27
DKPA200801478 2008-10-27
PCT/EP2009/005217 WO2010006809A2 (en) 2008-07-18 2009-07-17 Medical use of the radical scavenger and antioxidant alpha-1-microglobulin

Publications (1)

Publication Number Publication Date
CA2730531A1 true CA2730531A1 (en) 2010-01-21

Family

ID=41550762

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2730531A Abandoned CA2730531A1 (en) 2008-07-18 2009-07-17 Medical use of the radical scavenger and antioxidant alpha-1-microglobulin

Country Status (12)

Country Link
US (1) US10350268B2 (enExample)
EP (2) EP2313106B1 (enExample)
JP (3) JP5694928B2 (enExample)
AU (1) AU2009270435B2 (enExample)
CA (1) CA2730531A1 (enExample)
DK (2) DK2313106T3 (enExample)
ES (2) ES2614490T3 (enExample)
HR (2) HRP20160760T1 (enExample)
HU (2) HUE030274T2 (enExample)
PL (2) PL2313106T3 (enExample)
PT (1) PT2638915T (enExample)
WO (1) WO2010006809A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
NZ578077A (en) 2007-02-12 2012-04-27 Stefan Hansson Diagnosis of preeclampsia using free foetal haemoglobin
JP5793076B2 (ja) 2008-05-28 2015-10-14 プロセラ バイオロジクス， インコーポレイテッド 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
PL2900254T3 (pl) * 2012-09-05 2017-02-28 A1M Pharma Ab Alfa-1 mikroglobulina do użycia w leczeniu chorób związanych z mitochondriami
US9572872B2 (en) 2012-09-09 2017-02-21 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
EP3102224B1 (en) 2013-12-20 2019-02-20 NephroGenesis, LLC. Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis
SG11201807352XA (en) * 2016-03-18 2018-09-27 A1M Pharma Ab Novel alpha-1-microglobulin derived proteins and their use
CA3036553A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
WO2018094023A2 (en) * 2016-11-16 2018-05-24 Anand Prasad Cyclic dipeptides and wound healing
KR102587810B1 (ko) 2017-04-25 2023-10-11 프로테라 바이오로직스, 인크. 인터-알파 억제제 단백질을 정량화하는 방법
EP3703729A1 (en) * 2017-11-03 2020-09-09 Guard Therapeutics International AB Use of alpha-1-microglobulin for protection of bone marrow cells
JP6906807B2 (ja) * 2018-08-31 2021-07-21 一般社団法人クラインシュタイン医工学パースペクティブ 透析装置
AU2024219294A1 (en) 2023-02-08 2025-07-10 Guard Therapeutics International AB Alpha-1-microglobulin derived peptide fragments and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) * 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
DE10125883A1 (de) 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
AR045074A1 (es) * 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
JP2007001922A (ja) 2005-06-23 2007-01-11 Asahi Kasei Pharma Kk 透析患者における腎疾患改善剤、又は機能性食品
US20070292421A1 (en) 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
NZ578077A (en) 2007-02-12 2012-04-27 Stefan Hansson Diagnosis of preeclampsia using free foetal haemoglobin

Also Published As

Publication number Publication date
WO2010006809A2 (en) 2010-01-21
JP5694928B2 (ja) 2015-04-01
AU2009270435B2 (en) 2014-10-16
PT2638915T (pt) 2017-01-10
EP2638915B1 (en) 2016-10-19
JP2016102125A (ja) 2016-06-02
AU2009270435A1 (en) 2010-01-21
HRP20160760T1 (hr) 2016-08-12
HUE027953T2 (en) 2017-01-30
DK2638915T3 (en) 2017-01-30
EP2638915A1 (en) 2013-09-18
JP2015071620A (ja) 2015-04-16
PL2313106T3 (pl) 2016-08-31
US10350268B2 (en) 2019-07-16
HUE030274T2 (en) 2017-05-29
WO2010006809A3 (en) 2010-05-27
JP6175478B2 (ja) 2017-08-02
DK2313106T3 (en) 2016-07-25
JP6406987B2 (ja) 2018-10-17
HRP20161808T1 (hr) 2017-02-24
ES2571956T3 (es) 2016-05-27
US20110190208A1 (en) 2011-08-04
PL2638915T3 (pl) 2017-04-28
ES2614490T3 (es) 2017-05-31
JP2012505154A (ja) 2012-03-01
EP2313106B1 (en) 2016-03-30
EP2313106A2 (en) 2011-04-27

Similar Documents

Publication Publication Date Title
AU2009270435B2 (en) Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
Kılıç et al. The effects of dexmedetomidine on mesenteric arterial occlusion-associated gut ischemia and reperfusion-induced gut and kidney injury in rabbits
Zhu et al. Neuroprotective actions of taurine on hypoxic-ischemic brain damage in neonatal rats
Zhao et al. Nrf2 to pre-condition the brain against injury caused by products of hemolysis after ICH
CA2834516A1 (en) Mfg-e8 and uses thereof
JP2018203756A (ja) ミトコンドリア関連疾患の治療に使用するためのα−１−ミクログロブリン
Alam et al. Resuscitation-induced pulmonary apoptosis and intracellular adhesion molecule-1 expression in rats are attenuated by the use of ketone Ringer’s solution
Maiese et al. Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology
CN105288598A (zh) 治疗缺氧诱导因子(hif)相关的状况的方法
JP2023500771A (ja) アネキシンａ５の用途
AU2014262273B2 (en) Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
CN114555630A (zh) 用于治疗脊髓损伤和/或髓鞘再生的肽的全身施用
JP2022533365A (ja) 出血性脳卒中後の有害な二次神経学的転帰を処置する際に使用するためのハプトグロビン
Kumar et al. A novel peptide derivative exhibits antiinflammatory and antioxidant activity in adjuvant induced arthritis in rats
Qiang et al. Expression and characterization of recombinant human milk fat globule-EGF factor VIII
McCormick et al. Clinically applicable thermal preconditioning attenuates leukocyte–endothelial interactions
RU2747121C1 (ru) Способ применения средства на основе модифицированного пероксиредоксина 2 человека для коррекции последствий ишемически-реперфузионного поражения почек
RU2405558C2 (ru) Лекарственный препарат для лечения гипоксических и токсических митохондриальных нарушений и способ его получения
Suzuki et al. Hemopexins suppress phorbol ester-induced necrosis of polymorphonuclear leucocytes
Özdemir-Kumral et al. Nesfatin-1 ameliorates sepsis-induced remote organ injury: the role of oxidant-antioxidant status and neutrophils
Dobryszycka Haptoglobin in the new millenium
Minaei et al. Protective effect of nano magnesium oxide on renal ischemia/reperfusion injury in male Wistar rats
JPWO2018008729A1 (ja) 虚血性疾患の治療剤
WO2017048157A1 (ru) Комбинаторная терапия для лечения геморрагического шока и последствий черепно-мозговой травмы
JP2021501750A (ja) 骨髄細胞の保護のためのアルファ−１−ミクログロブリンの使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140424

FZDE Discontinued

Effective date: 20200831